Allogeneic BMT is a curative treatment for patients with severe aplastic anemia (SAA). In particular, BMT from a HLA-identical sibling is an established treatment for children with acquired SAA, but the results of alternative donor (AD) transplantation have been less favorable because of the high rates of graft failure and severe acute GVHD. 1 However, recent data have shown improvements in the survival of patients receiving unrelated donor (UD) transplantation possibly due to better donor matching attributable to the use of high-resolution HLA typing data. 2 Two major studies have been performed in the setting of UD transplantation for SAA. The first is a Japanese study that reported 154 SAA patients undergoing UD transplantation using CY/TBI/anti-thymocyte globulin (ATG) and also CY/limited field irradiation/ ATG: 11% showed rejection whereas 56% survived. 3 The second involves a group in the USA, which reported a study that tested the deescalating doses of TBI (from 6 to 2 Gy) in combination with CY and ATG in UD transplantation for SAA, and showed the best outcomes in patients receiving 2 Gy, with 8 of 13 patients surviving. 4 The current series presents the results of AD transplantation in 13 SAA patients undergoing BMT with the addition of low-dose irradiation to fludarabine (Flu)-based conditioning.
The characteristics of the 13 SAA patients who underwent AD BMT at Tokai University Hospital between September 2001 and May 2008 are shown in Table 1 . Of these 13 patients, 12 received prior immunosuppressive therapy, and all were transfusion dependent at the time of AD transplantation. Specifically, the donors were a UD for 11 patients and an HLA mismatched family member for 2 patients. The HLA-incompatible loci are described in Table 1 and ATG (thymoglobulin; Genzyme, Cambridge, MA, USA) 1.25 mg/kg once daily (i.v.) on days À5, À4, À3 and À2 (total dose 5 mg/kg) Unmanipulated BM was infused on day 0. Ovary and testis shielding during TAI was performed for all patients, and thyroid gland shielding was provided for five successive patients from patient 9 onwards to prevent secondary thyroid cancer. GVHD prophylaxis was carried out with short-term MTX (15 mg/m 2 on day 1; 10 mg/m 2 on days 3, 6 and 11) and continuous i.v. infusion of tacrolimus 0.02-0.03 mg/kg. Mycophenolate mofetil 15 mg/kg per day (days 14-42) was added for patients who received antigen mismatched donor marrow. All patients were administered G-CSF from day 5 until their neutrophil counts exceeded 1.5 Â 10 9 /L. The clinical outcomes of BMT are summarized in Table 2 . All patients achieved neutrophil engraftment (40.5 Â 10 9 /L) at a median of day þ 20 (range, 12-25 days), but one patient showed rejection 31 days after transplantation caused by hemophagocytic syndrome following sepsis. This patient received a second successful BMT from his haploidentical mother with Flu, melphalan and TAI conditioning. The day 30 chimerism by STR analysis of BM mononuclear cells was 100% in all but one patient (96%), and that of PBMCs was 100% in all patients more than 12 months after BMT. None of the patients showed grade III/IV regimen-related toxicity using the Bearman's criteria at any evaluation point. All patients are alive and well; their hemograms are normal with complete donor cell engraftment, and with a Lansky/Karnofsky score of 100% at a median of 64 months following BMT. There were no malignancies observed during the follow-up period.
Both graft rejection and severe acute GVHD were the major causes of failure in the AD BMT for SAA, particularly in mismatched UD. 5 The risk of rejection can be reduced with the addition of 8-10 Gy irradiation, 3 but this is associated with delayed effects on growth, pulmonary toxicity and secondary malignancies. 6 One approach to improve conditioning by the European Group for Blood and Marrow Transplantation SAA working party has been the substitution of TBI with Flu to reduce the risk of secondary tumors. 7 The results are also less favorable in older patients aged more than 15 years, with 61% survival and 32% rejection. Although radiation increases the risk of secondary tumors, very low dose irradiation (2-3 Gy) may reduce such risk, and this procedure is used in many regimens for UD transplantations such as in our study to achieve a stable engraftment. 8 We previously reported that a Flu-based conditioning regimen (low-dose TAI/Flu/CY/ ATG) that was used in 27 Fanconi anemia patients for AD transplantations led to successful engraftment in 25 of 26 evaluable patients without severe toxicity. 9 The advantage of Flu may be its strong cytotoxic activity against lymphocytes, which consistently prolongs immunosuppression, thus facilitating the engraftment of hematopoietic stem cells. The combination of Flu and low-dose TAI might establish a definitive engraftment in SAA patients transplanted from an AD.
In addition, the total dose of CY (3000 mg/m 2 ) was reduced by about half from the standard dose at 200 mg/kg for SAA patients to reduce cardiac complications, 10 as many SAA patients have cardiac dysfunction due to persistent anemia and/or iron accumulation.
The second goal of this series was to prevent severe acute GVHD after AD transplantation including mismatched transplants. None of the patients in our study developed grade III/IV acute GVHD. The low-dose ATG administered prior to transplantation might exert a preventive effect on GVHD in conjunction with tacrolimus and short-term MTX. 9 Taken together, this series demonstrated that a conditioning regimen containing low-dose irradiation and a minimum dose of Flu, CY and ATG could enable the successful engraftment of AD marrow in children with SAA. Long-term follow-up and larger studies are warranted to confirm the high engraftment rates and absence of severe GVHD and secondary malignancies.
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